Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Unknown × Disease Progression × Temozolomide × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Glioblastoma 40 Glioma 15 Melanoma 11 Central Nervous System Neoplasms 11 Astrocytoma 11 Brain Neoplasms 10 Oligodendroglioma 7 Gliosarcoma 5 Leiomyosarcoma 3 Small Cell Lung Carcinoma 2 Sarcoma 2 Recurrence 2 Neoplasms, Neuroepithelial 2 Neoplasm Metastasis 2 Lymphoma 2 Ependymoma 2 Diffuse Intrinsic Pontine Glioma 2 Breast Neoplasms 2 Uveal Melanoma 1 Sarcoma, Synovial 1 Sarcoma, Ewing 1 Sarcoma, Endometrial Stromal 1 Sarcoma, Alveolar Soft Part 1 Rhabdomyosarcoma 1 Rhabdoid Tumor 1 Recurrent Extensive Stage Small Cell Lung Carcinoma 1 Rectal Neoplasms 1 Pituitary Neoplasms 1 Pheochromocytoma 1 Paraganglioma 1

Interventions

pomalidomide 1 pembrolizumab 1 Temozolomide 1 Tamsulosin 1 Sodium Selenite 1 Radiomics 1 Hepatectomy 1 Epirubicin 1 Dexamethasone 1 Cyclophosphamide 1 Bevacizumab 1 10-propargyl-10-deazaaminopterin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02761070 2023-03-08

RE-GEND

Kyorin University

Phase 3 Unknown

Glioblastoma, Recurrence, Disease Progression

Data powered by HemOnc (CC BY 4.0) Colophon ⚡